in ovarian cancer: a study of interobserver variability . Gynecol Oncol 1994 ; 55 : 87 – 90 . 9. Gordon AN Fleagle JT Guthrie D . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin
Search Results
The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer
Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim
Edited by Kerrin G. Robinson
Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer
Joyce Liu and Ursula Matulonis
. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol 2001 ; 19 : 3312 – 3322 . 15. Cantu MG Buda A Parma G . Randomized controlled trial of single
Thinking Outside the Box About Screening for Ovarian Cancer: The Nose Knows!
Robert J. Morgan
Ovarian (PLCO) Cancer Screening randomized controlled trial . JAMA 2011 ; 305 : 2295 – 2303 . 6 Horvath G Jarverud GA Jarverud S Horvath I . Human ovarian carcinomas detected by specific odor . Integr Cancer Ther 2008 ; 7 : 76 – 80
QIM21-087: Genetic Testing of Newly Diagnosed Ovarian Cancer Patients in a Regional Cancer Center in Appalachia
Hassaan Jafri, Isna Khan, and Nadim Bou Zgheib
large B-cell lymphoma, Seromucinous ovarian carcinoma, Borderline mucinous ovarian tumor, Borderline serous ovarian tumor). In the remaining 47 patients, 8(17%) were not offered genetic testing, 10 (21%) were either offered genetic testing but it was not
Re: “Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course”
Frederick Klauschen, Hendrik Bläker, and Albrecht Stenzinger
primary appears less likely from a pathologic point of view. Although we contend that a definitive diagnosis would not rely on morphology alone but would require immunohistochemistry, the morphology should have prompted considering ovarian carcinoma as one
Indications for Minimally Invasive Surgery for Ovarian Cancer
Ernest S. Han and Mark Wakabayashi
-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer—adjuvant chemotherapy in ovarian neoplasm trial . J Natl Cancer Inst 2003 ; 95 : 113 – 125 . 8. Trimbos JB Parmar M Vergote I . International collaborative ovarian
Highlights of the NCCN Oncology Research Program
)–positive, triple-negative (estrogen receptor–negative, HER2/neu-negative, progesterone receptor–negative) breast cancer, breast carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, uterine corpus carcinoma, and ovarian cancer
Oncology Research Program
; breast carcinoma; fallopian tube carcinoma; ovarian carcinoma; primary peritoneal carcinoma; uterine corpus carcinoma; and ovarian cancer Institution: City of Hope Comprehensive Cancer Center This phase I trial is studying the side effects and best
Highlights of the NCCN Oncology Research Program
, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, and uterine corpus carcinoma Institution: City of Hope National Medical Center This phase I trial evaluates the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of
Oncology Research Program
, ovarian carcinoma, primary peritoneal carcinoma, uterine corpus carcinoma, and ovarian cancer Institution: City of Hope National Medical Center This phase I trial is studying the side effects and best dose of mirvetuximab soravtansine (IMGN853) and
